Fig. 8: ZLN005 augments the CD8+ T cell-mediated antitumor immune response in CRC. | Cell Death Discovery

Fig. 8: ZLN005 augments the CD8+ T cell-mediated antitumor immune response in CRC.

From: DNMBP-AS1/hsa-miR-30a-5p/PGC1α axis suppresses tumor progression of colorectal cancer by inhibiting PKM2-mediated Warburg effect and enhance anti-PD-1 therapy efficacy

Fig. 8

A TIMER algorithm employed to examine the correlations between PGC1α expression and CD8 + T cells immune infiltration score. B PD1 expression levels were lower in the PGC1α high expression group. C TIDE scores were lower in the PGC1α high-expression group. D Schematic diagram of administration cycles in mice. Tumor growth (E, F) and tumor burdens (G) of MC38 xenografts treated with control (vehicle) or ZLN005 combined with IgG2a or anti–PD-1 mAb (n = 5). H, I Quantification of tumor-infiltrating immune cells, GZMB+ CD8+ cells and IFN-γ+ CD8+ cells analyzed by flow cytometry using the indicated cell surface markers and in control and ZLN005 group. *P < 0.05 or **P < 0.01 indicates significant differences from the vehicle group as assessed by a one-way ANOVA with a post hoc Dunnett’s test.

Back to article page